Important information regarding cookies and
By using this website, you consent to the use of cookies in accordance with the IMB Cookie Policy. For more information on cookies, see our Cookie Policy.
Full Version | Search

The Irish Medicines Board -

IMB Logo

Revlimid (lenalidomide) - Important Safety Information from Celgene as approved by the Irish Medicines Board

12 April 2011

Important Safety Information communication from Celgene regarding the potential risk of second primary malignancies in patients treated with Revlimid (lenalidomide).

Important Safety Information - Revlimid

Date Printed: 17 April 2014

© Irish Medicines Board 2014 | Developed by Engine Solutions

Address: Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland.
Tel: 353-1-676 4971